Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL1743035

LEBRIKIZUMAB
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
No structure available
ChEMBL ↗

Basic Information

ChEMBL ID CHEMBL1743035
Name LEBRIKIZUMAB
Phase Approved
Structure Type SEQ
Therapeutic ✓ Yes

Known Names

Ebglyss Lebrikizumab Lebrikizumab-lbkz MILR-1444A MILR1444A PRO-301444 PRO-301444 RG-3637 PRO301444 RO-5490255 Tnx-650
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
10
Known Names
6
Indications
2
Mechanisms

Drug Information

Molecule Type Antibody
First Approval 2023
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Parenteral
USAN Stem -mab; -mab
USAN Year 2009

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Interleukin-13 inhibitor INHIBITOR Interleukin-13 ✓ ✓
Interleukin-13 inhibitor INHIBITOR Interleukin-13 ✓ ✓

Indications

Dermatitis, Atopic Eczema Asthma Idiopathic Pulmonary Fibrosis Pulmonary Disease, Chronic Obstructive Hodgkin Disease

ATC Classification

D11AH10
lebrikizumab
Level 1: DERMATOLOGICALS
Level 2: OTHER DERMATOLOGICAL PREPARATIONS

Data from ChEMBL 36 via Core Engine